AAP
FLNA

Arax Advisory Partners’s Filana Therapeutics FLNA Stock Holding History

Arax Advisory Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680 Sell
368
-77
-17% -$159 ﹤0.01% 3370
2025
Q4 		$882 Hold
445
– – ﹤0.01% 3516
2025
Q3 		$1.29K Hold
445
– – ﹤0.01% 3200
2025
Q2 		$806 Hold
445
– – ﹤0.01% 2850
2025
Q1 		$668 Buy
+445
New +$1.12K ﹤0.01% 2463

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Arax Advisory Partners's FLNA Position: Q1 2026 in Review

Arax Advisory Partners reduced its Filana Therapeutics (FLNA) stake by 17% in Q1 2026, selling an estimated $159 and leaving 368 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #3370.

Arax Advisory Partners first reported a position in FLNA in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.29K in Q3 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Arax Advisory Partners held 368 shares of Filana Therapeutics worth $680 as of Q1 2026.
  • Arax Advisory Partners sold 77 Filana Therapeutics shares in Q1 2026, an estimated $159.
  • Filana Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3370 holding.
  • Arax Advisory Partners first reported a position in Filana Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Arax Advisory Partners's Filana Therapeutics position peaked at $1.29K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.